ZA200006034B - Biologically degradable cement exhibiting improved properties. - Google Patents
Biologically degradable cement exhibiting improved properties. Download PDFInfo
- Publication number
- ZA200006034B ZA200006034B ZA200006034A ZA200006034A ZA200006034B ZA 200006034 B ZA200006034 B ZA 200006034B ZA 200006034 A ZA200006034 A ZA 200006034A ZA 200006034 A ZA200006034 A ZA 200006034A ZA 200006034 B ZA200006034 B ZA 200006034B
- Authority
- ZA
- South Africa
- Prior art keywords
- tcp
- mixture according
- cag
- mixture
- phosphate
- Prior art date
Links
- 239000004568 cement Substances 0.000 title claims description 36
- 230000001747 exhibiting effect Effects 0.000 title 1
- 239000001506 calcium phosphate Substances 0.000 claims description 68
- 239000000203 mixture Substances 0.000 claims description 68
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 57
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 48
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 48
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 48
- 239000002245 particle Substances 0.000 claims description 29
- 210000000988 bone and bone Anatomy 0.000 claims description 20
- 229910019142 PO4 Inorganic materials 0.000 claims description 18
- 239000011575 calcium Substances 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 12
- 239000003242 anti bacterial agent Substances 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 10
- 239000000645 desinfectant Substances 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- 239000011734 sodium Substances 0.000 claims description 10
- 239000011777 magnesium Substances 0.000 claims description 9
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 8
- 235000011010 calcium phosphates Nutrition 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 7
- 239000010452 phosphate Substances 0.000 claims description 7
- 229910052749 magnesium Inorganic materials 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- 239000007943 implant Substances 0.000 claims description 4
- 150000002484 inorganic compounds Chemical class 0.000 claims description 4
- 229910010272 inorganic material Inorganic materials 0.000 claims description 4
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 claims description 3
- 241001286462 Caio Species 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 3
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 claims description 3
- OJYGBLRPYBAHRT-UHFFFAOYSA-N alphachloralose Chemical compound O1C(C(Cl)(Cl)Cl)OC2C(O)C(C(O)CO)OC21 OJYGBLRPYBAHRT-UHFFFAOYSA-N 0.000 claims description 2
- 229910052586 apatite Inorganic materials 0.000 claims description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 235000010216 calcium carbonate Nutrition 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 239000007900 aqueous suspension Substances 0.000 claims 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims 1
- 235000019700 dicalcium phosphate Nutrition 0.000 claims 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 12
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 12
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 12
- 229940038472 dicalcium phosphate Drugs 0.000 description 12
- 229940088710 antibiotic agent Drugs 0.000 description 9
- 238000002156 mixing Methods 0.000 description 7
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical group [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 7
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 6
- 229930182566 Gentamicin Natural products 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229960002518 gentamicin Drugs 0.000 description 6
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 6
- 239000007788 liquid Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 4
- RDEIXVOBVLKYNT-HDZPSJEVSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-[(1r)-1-aminoethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2 Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)[C@@H](C)N)N)[C@@H](N)C[C@H]1N.O1[C@H]([C@@H](C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-HDZPSJEVSA-N 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 239000012620 biological material Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 244000052616 bacterial pathogen Species 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- 206010031252 Osteomyelitis Diseases 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- UFUVLHLTWXBHGZ-MGZQPHGTSA-N [(2r,3r,4s,5r,6r)-6-[(1s,2s)-2-chloro-1-[[(2s,4r)-1-methyl-4-propylpyrrolidine-2-carbonyl]amino]propyl]-4,5-dihydroxy-2-methylsulfanyloxan-3-yl] dihydrogen phosphate Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@@H](SC)O1 UFUVLHLTWXBHGZ-MGZQPHGTSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- 229960001139 cefazolin Drugs 0.000 description 2
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960002291 clindamycin phosphate Drugs 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- GBNXLQPMFAUCOI-UHFFFAOYSA-H tetracalcium;oxygen(2-);diphosphate Chemical compound [O-2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GBNXLQPMFAUCOI-UHFFFAOYSA-H 0.000 description 2
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Chemical compound CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- HECLRDQVFMWTQS-UHFFFAOYSA-N Dicyclopentadiene Chemical compound C1C2C3CC=CC3C1C=C2 HECLRDQVFMWTQS-UHFFFAOYSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010031264 Osteonecrosis Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001251 acridines Chemical class 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 239000003462 bioceramic Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000002639 bone cement Substances 0.000 description 1
- 239000000316 bone substitute Substances 0.000 description 1
- 238000001354 calcination Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- -1 chlorhexidine and Chemical class 0.000 description 1
- 229960004714 clindamycin palmitate Drugs 0.000 description 1
- OYSKUZDIHNKWLV-PRUAPSLNSA-N clindamycin palmitate Chemical compound O1[C@H](SC)[C@H](OC(=O)CCCCCCCCCCCCCCC)[C@@H](O)[C@@H](O)[C@H]1[C@@H]([C@H](C)Cl)NC(=O)[C@H]1N(C)C[C@H](CCC)C1 OYSKUZDIHNKWLV-PRUAPSLNSA-N 0.000 description 1
- 239000011362 coarse particle Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- CGMRCMMOCQYHAD-UHFFFAOYSA-J dicalcium hydroxide phosphate Chemical compound [OH-].[Ca++].[Ca++].[O-]P([O-])([O-])=O CGMRCMMOCQYHAD-UHFFFAOYSA-J 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/02—Surgical adhesives or cements; Adhesives for colostomy devices containing inorganic materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Surgery (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19813614A DE19813614A1 (de) | 1998-03-27 | 1998-03-27 | Bio-Zemente mit verbesserten Eigenschaften |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200006034B true ZA200006034B (en) | 2001-08-10 |
Family
ID=7862589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200006034A ZA200006034B (en) | 1998-03-27 | 2000-10-26 | Biologically degradable cement exhibiting improved properties. |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1066065A1 (ja) |
| JP (1) | JP2002509766A (ja) |
| CN (1) | CN1295485A (ja) |
| AU (1) | AU2933699A (ja) |
| CA (1) | CA2325740A1 (ja) |
| DE (1) | DE19813614A1 (ja) |
| HU (1) | HUP0101520A3 (ja) |
| PL (1) | PL342733A1 (ja) |
| WO (1) | WO1999049906A1 (ja) |
| ZA (1) | ZA200006034B (ja) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1153621A1 (de) * | 2000-05-12 | 2001-11-14 | MERCK PATENT GmbH | Biozemente auf TCP-PHA-Basismischung mit verbesserter Kompressionsfestigkeit |
| EP1335887A4 (en) | 2000-10-16 | 2004-06-23 | Univ South Carolina | BIOCOMPATIBLE CEMENT CONTAINING CALCIUM PHOSPHATE REACTIVE NANOPARTICLES AND METHODS OF MAKING AND USING SUCH A CEMENT |
| JP2002291866A (ja) * | 2001-04-03 | 2002-10-08 | Ngk Spark Plug Co Ltd | リン酸カルシウムセメント粉体及びリン酸カルシウムセメント |
| DE10249625B4 (de) * | 2002-10-21 | 2005-08-04 | BAM Bundesanstalt für Materialforschung und -prüfung | Pulvergemisch für resorbierbare Calciumphosphat-Biozemente und ihre Verwendung |
| BRPI0617086B8 (pt) | 2005-09-09 | 2021-06-22 | Agnovos Healtcare Llc | cimento composto substituto de enxerto ósseo e artigos dele originados |
| EP2077126A1 (en) * | 2008-01-07 | 2009-07-08 | Graftys | Analgesic apatitic calcium-phosphate cement |
| JP5478872B2 (ja) * | 2008-11-05 | 2014-04-23 | 国立大学法人東北大学 | 人工骨材 |
| US10342893B2 (en) | 2012-01-31 | 2019-07-09 | The University Of Toledo | Injectable, biodegradable bone cements and methods of making and using same |
| US9487443B2 (en) * | 2014-03-14 | 2016-11-08 | Ricoh Company, Ltd. | Layer stack formation powder material, powder layer stack formation hardening liquid, layer stack formation material set, and layer stack object formation method |
| CN106587681B (zh) * | 2016-12-06 | 2019-04-12 | 南昌大学 | 一种绿色建筑材料-生物水泥的制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4668295A (en) * | 1985-04-25 | 1987-05-26 | University Of Dayton | Surgical cements |
| DE3613213A1 (de) * | 1986-04-18 | 1987-10-22 | Merck Patent Gmbh | Tricalciumphosphat fuer implantationsmaterialien |
| US5569442A (en) * | 1994-11-04 | 1996-10-29 | Norian Corporation | Reactive tricalcium phosphate compositions and uses |
-
1998
- 1998-03-27 DE DE19813614A patent/DE19813614A1/de not_active Withdrawn
-
1999
- 1999-03-17 AU AU29336/99A patent/AU2933699A/en not_active Abandoned
- 1999-03-17 PL PL99342733A patent/PL342733A1/xx unknown
- 1999-03-17 HU HU0101520A patent/HUP0101520A3/hu unknown
- 1999-03-17 CA CA002325740A patent/CA2325740A1/en not_active Abandoned
- 1999-03-17 JP JP2000540868A patent/JP2002509766A/ja active Pending
- 1999-03-17 EP EP99910351A patent/EP1066065A1/de not_active Withdrawn
- 1999-03-17 WO PCT/EP1999/001738 patent/WO1999049906A1/de not_active Application Discontinuation
- 1999-03-17 CN CN99804569.1A patent/CN1295485A/zh active Pending
-
2000
- 2000-10-26 ZA ZA200006034A patent/ZA200006034B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL342733A1 (en) | 2001-07-02 |
| EP1066065A1 (de) | 2001-01-10 |
| CN1295485A (zh) | 2001-05-16 |
| AU2933699A (en) | 1999-10-18 |
| JP2002509766A (ja) | 2002-04-02 |
| CA2325740A1 (en) | 1999-10-07 |
| DE19813614A1 (de) | 1999-09-30 |
| HUP0101520A2 (hu) | 2001-11-28 |
| WO1999049906A1 (de) | 1999-10-07 |
| HUP0101520A3 (en) | 2001-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001271209B2 (en) | A composition for an injectable bone mineral substitute material | |
| US6425949B1 (en) | Hydraulic surgical cement | |
| US8715410B2 (en) | Strontium-apatite cement preparation cements formed therefrom, and use thereof | |
| US5149368A (en) | Resorbable bioactive calcium phosphate cement | |
| JP3110762B2 (ja) | 吸収可能な生体活性リン酸塩含有セメント | |
| US6706273B1 (en) | Composition for implantation into the human and animal body | |
| CA2518104C (en) | Artificial bone mineral substitute for in vivo hardening | |
| US7540914B2 (en) | Magnesium ammonium phosphate cement composition | |
| KR101061308B1 (ko) | 스트론튬-아파타이트-접합 제제 및 이로부터 형성된접합제 및 이의 용도 | |
| JPH0222113A (ja) | リン酸カルシウム鉱物の製造方法 | |
| AU2001271209A1 (en) | A composition for an injectable bone mineral substitute material | |
| ZA200006034B (en) | Biologically degradable cement exhibiting improved properties. | |
| EP1023032B1 (en) | Hydraulic surgical cement | |
| US8540815B2 (en) | Preparation for magnesium ammonium phosphate cements | |
| CZ20003459A3 (cs) | Biologicky odbouratelný cement se zlepšenými vlastnostmi |